Sensitive tumor detection with magnetomotive imaging

利用磁动成像进行灵敏的肿瘤检测

• 批准号: 8384090
• 负责人: Xiaohu Gao
• 金额: $ 46.5万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8384090
• 关键词: Academy; Acoustics; Address; Adverse effects; Animal Model; Animals; Area; Binding; Biological; Biological Markers; Biomedical Engineering; Censuses; Clinical; Code; Collaborations; Communication; Contrast Media; Coupled; Detection; Development; Diagnosis; Diagnostic; Elasticity; Electromagnetics; Engineering; Environment; Faculty; Feedback; Fever; Fostering; Future; Goals; Image; Imaging technology; Interdisciplinary Study; Lasers; Life; Magnetism; Malignant Neoplasms; Medical; Medicine; Modeling; Molecular; Monitor; Mus; Nanotechnology; Nature; Neoplasm Metastasis; Noise; Nude Mice; Optics; Performance; Phase; Positioning Attribute; Preparation; Procedures; Property; Prostatic Neoplasms; Records; Research; Research Personnel; SCID Mice; Sampling; Series; Signal Transduction; Specificity; System; Techniques; Technology; Technology Assessment; Temperature; Testing; Therapeutic; Therapeutic Effect; Time; Tissues; Transducers; Translations; Tumor Biology; Ultrasonography; Urology; Work; Xenograft Model; absorption; anticancer research; base; bioimaging; college; computerized data processing; design; detector; effective therapy; flexibility; hyperthermia treatment; image guided therapy; imaging modality; imaging probe; improved; in vivo; innovation; instrument; instrumentation; medical schools; member; molecular imaging; nanobiotechnology; nanoparticle; nanoprobe; new technology; novel; outcome forecast; particle; research study; response; success; technology development; tumor; uptake

DESCRIPTION (provided by applicant): This application directly addresses "PQ13. Can tumors be detected when they are two to three orders of magnitude smaller than those currently detected with in vivo imaging modalities?" To date molecular imaging technologies have had limited clinical impact to date for a number of reasons. One of the primary ones is the inadequate contrast specificity of molecular contrast agents due to non-specific agent binding and background signals from tissue. Major increase in detection sensitivity would provide a fundamental change in how we diagnose and treat cancers. In this context, the overarching goal of this project is to develop an ultrasensitive platform technology based on a recent breakthrough we made on magnetomotion-based imaging-contrast enhancement (Nat. Commun. 2010). We have shown improvement of imaging S/N ratio of 3 orders or magnitude in phantoms by incorporating magnetic properties into imaging contrast agents. Through this project, we plan to further develop this innovative and powerful background suppression technique for in vivo tumor imaging and image-guided therapy. We will use photoacoustic imaging as a model, but the innovative concept and algorism can be expanded to virtually any other molecular imaging modalities involving contrast agents. This platform technology is also compatible with future major developments in the field of biomedical imaging, such as development of more specific probes and more sensitive detectors. PUBLIC HEALTH RELEVANCE: The primary goal of this application is to develop an innovative, powerful, and flexible platform technology that can improve in vivo tumor imaging sensitivity by 2-3 orders of magnitude. Recent advances in molecular imaging have produced a number of outstanding agents and instruments, yet ultrasensitive detection of tumor in vivo has not been realized, which at least can be partially attributed to the strong background that obscure specific signals since what really matters is signal-to-noise ratio rather than absolute detection sensitivity. In this context, we propose to develop a new imaging strategy based on coupled contrast agents and magnetomotive imaging, which is capable of efficiently removing background for improved tumor detection limit.

描述（由申请人提供）：本申请直接解决“PQ13。当肿瘤比目前体内成像方式检测到的肿瘤小两到三个数量级时，能否检测到肿瘤？”迄今为止，由于多种原因，分子成像技术的临床影响有限。主要问题之一是由于非特异性试剂结合和来自组织的背景信号，分子造影剂的对比特异性不足。检测灵敏度的大幅提高将为我们诊断和治疗癌症的方式带来根本性的改变。在此背景下，该项目的总体目标是基于我们最近在基于磁运动的成像对比度增强方面取得的突破（Nat. Commun. 2010），开发一种超灵敏平台技术。我们已经证明，通过将磁性特性融入成像造影剂中，模型中的成像信噪比可提高 3 个数量级或数量级。通过这个项目，我们计划进一步开发这种创新且强大的背景抑制技术，用于体内肿瘤成像和图像引导治疗。我们将使用光声成像作为模型，但创新概念和算法可以扩展到几乎任何其他涉及造影剂的分子成像模式。该平台技术还与生物医学成像领域未来的重大发展兼容，例如开发更特异的探针和更灵敏的探测器。 公共健康相关性：该应用的主要目标是开发一种创新、强大且灵活的平台技术，可以将体内肿瘤成像灵敏度提高 2-3 个数量级。分子成像的最新进展已经产生了许多出色的试剂和仪器，但体内肿瘤的超灵敏检测尚未实现，这至少可以部分归因于掩盖特定信号的强烈背景，因为真正重要的是信号传递-噪声比而不是绝对检测灵敏度。在这种背景下，我们建议开发一种基于耦合造影剂和磁动成像的新成像策略，该策略能够有效去除背景以提高肿瘤检测限。